Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077308 · ClinicalTrials.gov registry record
Rare Diseases Clinical Research Network: Neurophysiological Correlates
A clinical trial of Rett Syndrome, Preserved Speech Variant and Mecp2 Duplication Syndrome, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 185
- Enrollment target
- 5
- Study locations
NCT03077308 is a study of Rett Syndrome, Preserved Speech Variant and Mecp2 Duplication Syndrome that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 185 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT03077308, a study of Rett Syndrome, Preserved Speech Variant and Mecp2 Duplication Syndrome, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 185 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overall purpose of this project is to advance understanding of the neurophysiological features of Rett syndrome (RTT), MECP2 Duplication (MECP2 Dup) and RTT-related disorders (CDKL5, FOXG1) to gain insight into disease pathogenesis, with an emphasis on identifying biomarkers of disease evolution and severity. This specific study is intertwined to the core study Natural History of Rett Syndrome and Related Disorders (RTT5211), which characterizes range of clinical involvement and genotype-phenotype correlations and will provide phenotypical data for determining the clinical relevance of the neurophysiologic parameters; study subjects here are co- and primarily enrolled in RTT5211. The proposed studies will serve as basis of future translational investigations, including further refinement of biomarkers, development of outcome measures, and clinical trials per se.
Conditions Studied
Interventions
- PROCEDURE Auditory and Visual Event-related Potentials and EEG
Study Locations (5)
Colorado
- University of Colorado Denver - Denver
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Cincinnati Children's Hospital - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2017-01-02 |
| Est. Completion | 2021-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03077308
The ClinicalTrials.gov registry entry for NCT03077308 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Rett Syndrome, Preserved Speech Variant appearing as the primary indexed condition, and to 1 intervention - of which Auditory and Visual Event-related Potentials and EEG is the first listed.
NCT03077308 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT03077308 about?
NCT03077308 is a clinical study titled "Rare Diseases Clinical Research Network: Neurophysiological Correlates". The overall purpose of this project is to advance understanding of the neurophysiological features of Rett syndrome (RTT), MECP2 Duplication (MECP2 Dup) and RTT-related disorders (CDKL5, FOXG1) to gain insight into disease pathogenesis, with an emphasis on identifying biomarkers of disease evolution...
What is the current status of trial NCT03077308?
This trial is currently completed. The enrollment target is 185 participants. The study started on 2017-01-02. Estimated completion is 2021-07-31.
What conditions does trial NCT03077308 study?
This clinical trial studies the following conditions: Rett Syndrome, Preserved Speech Variant, Mecp2 Duplication Syndrome, Rett-related Disorders.
What interventions are being tested in trial NCT03077308?
The interventions under investigation include: Auditory and Visual Event-related Potentials and EEG (PROCEDURE).
Who is sponsoring clinical trial NCT03077308?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03077308 being conducted?
This trial has 5 study locations across Colorado, Massachusetts, Ohio, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Rett Syndrome, Preserved Speech Variant
All registered trials for this condition
Mecp2 Duplication Syndrome
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.